On completion of the all-stock deal, MDP funds and WBA will own roughly 80% of the combined publicly traded company on a fully diluted basis, with current BioScrip shareholders holding the remainder, the companies said. Option Care CEO John Rademacher will lead the combined company.
"This is a compelling and complementary fit of two leading players in the U.S. infusion market," BioScrip CEO Daniel Greenleaf said in a statement. "Our expanded reach and broader array of offerings provide a key competitive advantage at a time when the demand for home and alternate site infusion services continues to grow."
Investors seemed to agree, pushing up BioScrip stock by 3.7% to $3.62 on Friday. Shares has risen as much as 20% in premarket trading.
Separately, BioScrip on Friday reported a fiscal fourth-quarter loss from continuing operations of $15.4 million, or 12 cents a share, compared to $15.1 million, or 14 cents, in the prior year. Net sales were $183.6 million compared to $178.5 million in the fourth quarter of 2017.
A Special Invitation: Do you want to learn more about planning for and living retirement from the nation's top experts, including Ed Slott and Robert Powell, the editor ofTheStreet's Retirement Daily? Want to learn how to create tax-efficient income in retirement and how to manage and mitigate all the risks you'll face in retirement? Then sign up to attend TheStreet's Retirement Strategies Symposium on April 6 in New York City. For a limited time, you can attend this extraordinary symposium for $149 -- a cost savings of $50 off the general admission price of $199. You can see the full day's agenda, learn about the guest speakers and sign up here for this special event.